USNA — USANA Health Sciences, Inc. stock price, charts and financials
QT45USANA Health Sciences, Inc.USANA Health Sciences, Inc. (NYSE: USNA) is a Consumer Defensive company in the Household & Personal Products industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 46.74 | EPS (ttm) | 0.47 | Insider Own | 47.51% | Shs Outstand | 18.46M | Perf Week | 3.71% |
| Market Cap | 408.22M | Forward P/E | 7.98 | EPS next Y | 2.77 | Insider Trans | -0.49% | Shs Float | 9.86M | Perf Month | 1.80% |
| Enterprise Value | 259.47M | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 7.63% | Perf Quarter | 16.06% |
| Income | 8.90M | P/S | 0.44 | EPS this Y | 351.06% | Inst Trans | - | Short Ratio | 6.77 | Perf Half Y | 1.98% |
| Sales | 926.00M | P/B | 0.75 | EPS next Y | 30.66% | ROA | 1.20% | Short Interest | 753.03K | Perf YTD | 12.63% |
| Book/sh | - | P/C | 24.47 | EPS next 5Y | 30.66% | ROE | 1.66% | 52W High | 33.39 -31.59% | Perf Year | -25.10% |
| Cash/sh | - | P/FCF | 137.86 | EPS past 3/5Y | -45.54% -37.03% | ROIC | 1.75% | 52W Low | 17.15 33.19% | Perf 3Y | -67.45% |
| Dividend Est. | - | EV/EBITDA | 3.24 | Sales past 3/5Y | -2.53% -4.01% | Gross Margin | 76.72% | Volatility | 3.75% 4.33% | Perf 5Y | -78.15% |
| Dividend TTM | - | EV/Sales | 0.28 | EPS Y/Y TTM | -78.54% | Oper. Margin | 5.30% | ATR (14) | 0.97 | Perf 10Y | -64.60% |
| Dividend Ex-Date | - | Quick Ratio | 1.69 | Sales Y/Y TTM | 8.30% | Profit Margin | 0.96% | RSI (14) | 54.08 | Recom | 2.88 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.51 | EPS Q/Q | -16.44% | SMA20 | 0.27% | Beta | 0.72 | Target Price | 35.00 |
| Payout | 0.00% | Debt/Eq | 0.03 | Sales Q/Q | 0.00% | SMA50 | 8.70% | Rel Volume | 0.63 | Prev Close | 22.11 |
| Employees | 1,570 | LT Debt/Eq | 0.02 | Earnings | Aug 04 | SMA200 | 11.68% | Avg Volume | 111.17K | Price | 22.84 |
| IPO Date | Apr 04, 1994 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 38.64% 3.74% | Net Debt/EBITDA | -1.86 | Volume | 69,893 | Change | 3.30% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-23-24 | Reiterated | DA Davidson | Neutral | $38 → $35 |
| Jul-25-24 | Reiterated | DA Davidson | Neutral | $46 → $38 |
| May-07-24 | Reiterated | DA Davidson | Neutral | $76 → $46 |
| Jul-07-22 | Downgrade | Jefferies | Hold → Underperform | |
| Apr-27-22 | Reiterated | DA Davidson | Neutral | $76 |
| Jul-03-19 | Downgrade | Sidoti & Co. | Buy → Neutral | |
| Apr-23-18 | Downgrade | Pivotal Research | Buy → Hold | |
| Jan-24-18 | Downgrade | Sidoti & Co. | Buy → Neutral | |
| May-03-17 | Upgrade | Pivotal Research | Hold → Buy | |
| May-01-17 | Downgrade | Pivotal Research | Buy → Hold |
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials, such as vitamin and mineral supplements for age group beginning with children 13 months of age; and food products that include meal replacement shakes, snack bars, and other related products for healthy weight management, digestive health, and energy and hydration. It offers Celavive, a skincare regimen for various skin care types and ethnicities; and all other products comprising materials and online tools for associates to build business and marketing of products The company sells its products through retail customers, a subscription model, and direct selling, as well as online. The company was founded in 1992 and is headquartered in Salt Lake City, Utah.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 1/3/2026 | FY 2024 12/28/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 926 | 925 | 855 | 921 | 999 | 1,186 | 1,135 | 1,061 | 1,189 | |
| Cost of Goods Sold Incl. D&A | 215 | 201 | 176 | 189 | 207 | 231 | 223 | 202 | 217 | |
| Gross Profit | 711 | 724 | 679 | 732 | 791 | 956 | 912 | 859 | 972 | |
| Selling, General and Administrative Excl. Other | 413 | 337 | 601 | 627 | 672 | 774 | 725 | 702 | 773 | |
| Research and Development | 0 | 0 | 12 | 11 | 12 | 11 | 11 | 10 | 10 | |
| Other Operating Expense | 249 | 337 | -1 | 1 | 0 | 0 | -1 | 1 | 0 | |
| Operating Income | 49 | 51 | 66 | 93 | 108 | 170 | 176 | 146 | 188 | |
| Interest Expense | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -8 | -8 | 10 | 10 | 1 | 1 | 2 | 4 | 3 | |
| Net Income Before Taxes | 40 | 42 | 76 | 102 | 109 | 171 | 178 | 150 | 192 | |
| Income Taxes | 31 | 30 | 34 | 39 | 39 | 54 | 53 | 50 | 65 | |
| Consolidated Net Income | 9 | 11 | 42 | 64 | 69 | 117 | 125 | 101 | 126 | |
| Net Income From Continuing Operations | 8 | 11 | 42 | 64 | 69 | 117 | 125 | 101 | 126 | |
| Net Income | 9 | 11 | 42 | 64 | 69 | 117 | 125 | 101 | 126 | |
| EPS (Recurring) | 0.47 | 0.58 | 2.20 | 3.33 | 3.60 | 5.78 | 5.89 | 4.44 | 5.36 | |
| EPS (Basic, Before Extraordinaries) | 0.47 | 0.58 | 2.20 | 3.33 | 3.60 | 5.78 | 5.89 | 4.44 | 5.36 | |
| EPS (Diluted) | 0.47 | 0.58 | 2.19 | 3.30 | 3.59 | 5.73 | 5.86 | 4.41 | 5.12 | |
| EBITDA | 80 | 82 | 99 | 123 | 130 | 193 | 201 | 169 | 188 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 48.60 | 33.52 | 16.30 | 16.24 | 14.82 | 17.66 | 13.16 | 17.81 | 22.99 | |
| Price To Sales Ratio | 0.44 | 0.40 | 0.79 | 1.11 | 1.01 | 1.71 | 1.43 | 1.70 | 2.38 | |
| Gross Margin | 76.78 | 78.27 | 79.42 | 79.48 | 79.18 | 80.61 | 80.35 | 80.96 | 81.75 | |
| Operating Margin | 5.29 | 5.51 | 7.72 | 10.10 | 10.81 | 14.33 | 15.51 | 13.76 | 15.81 | |
| Net Margin | 0.97 | 1.19 | 4.91 | 6.95 | 6.91 | 9.87 | 11.01 | 9.52 | 10.60 | |
| Shares Outstanding | 18 | 19 | 19 | 19 | 19 | 20 | 21 | 23 | 24 | |
| Market Capitalization | 411 | 369 | 678 | 1,018 | 1,011 | 2,024 | 1,619 | 1,807 | 2,826 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Benedict Peter | CHIEF INFORMATION OFFICER | Jul 25 '26 | Option Exercise | 0.00 | 598 | 0 | 598 | Jul 27 |
| Armstrong Kathryn Michelle | CHIEF SCIENTIFIC OFFICER | Jul 25 '26 | Option Exercise | 0.00 | 1,166 | 0 | 3,989 | Jul 27 |
| FULLER GILBERT A | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 1,632 | Jul 27 |
| Pelosi Peggie | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 6,996 | Jul 27 |
| Fleming John Turman | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 5,862 | Jul 27 |
| Ding Xia | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 8,882 | Jul 27 |
| WOOD TIMOTHY E | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 12,245 | Jul 27 |
| Winssinger Frederic J | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 9,733 | Jul 27 |
| Nixon J Scott | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 11,445 | Jul 27 |
| Neidig Brent | CHIEF COMMERCIAL OFFICER | Jun 16 '26 | Sale | 19.45 | 5,002 | 97,304 | 0 | Jun 18 |
| Neidig Brent | CHIEF COMMERCIAL OFFICER | Jun 15 '26 | Sale | 20.00 | 909 | 18,185 | 5,002 | Jun 16 |
| Neidig Brent | CHIEF COMMERCIAL OFFICER | Jun 12 '26 | Sale | 20.15 | 1,602 | 32,280 | 5,911 | Jun 16 |
| Jones Paul A. | CHIEF PEOPLE OFFICER | Jun 08 '26 | Sale | 18.50 | 5,561 | 102,879 | 0 | Jun 08 |
| Fleming John Turman | Director | Jun 01 '26 | Sale | 17.93 | 2,450 | 43,929 | 4,230 | Jun 01 |
| Jones Paul A. | CHIEF PEOPLE OFFICER | May 28 '26 | Sale | 18.95 | 6,813 | 129,106 | 5,561 | May 29 |